Ouabain Octahydrate

CAS: 11018-89-6

Ref. TR-O714500

Informação sobre produto

• Nome: Ouabain Octahydrate
• Sinónimos: Ouabain, 3ß-[(6-deoxy-a-l-mannopyranosyl)oxy]-1ß,5,11a,14,19-pentahydroxy- 5ß,14ß-card-20(22)-enolide, (1beta,3beta,5beta,11alpha)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide, (1beta,3beta,5beta,8xi,9xi,11alpha)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide, Card-20(22)-enolide, 3-[(6-deoxy-α-<span class="text-smallcaps">L</span>-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, hydrate (1:8), (1β,3β,5β,11α)-, Card-20(22)-enolide, 3-[(6-deoxy-α-<span class="text-smallcaps">L</span>-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, octahydrate, (1β,3β,5β,11α)-, G-Strophantin octahydrate, Strophantine octahydrate
• CAS: 11018-89-6

Descrição

Applications A cardiac glycoside that inhibits Na(+)/K(+) ATPase. It regulates transcription of MDR (increase, Pgp) and MRP (increase MRP1 and decrease CFTR, cyctic fibrosis transport receptor or cAMP-activated Cl- channel) genes, also alters localization of MRP1.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Padilha, A.S. et al.: Clin. Exp. Pharmacol. Physiol., 35, 801 (2008); Blaustein, M.P. et al.: Clin. Exp. Hypertens. 20, 691 (1998); van Huysse, J.W. et al.: Clin. Exp. Hypertens. 20, 657 (1998);

• Marca: TRC

Propriedades químicas

• Peso molecular: 728.77
• Fórmula: C₂₉H₄₄O₁₂•8H₂O
• Cor/forma: Neat
• InChI: , , , , , 8*1H2/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-, , , , InChI=1S/C29H44O12.8H2O/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31, , , /h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3, , , /m0......../s1, ,
• Chave InChI: InChIKey=LPMXVESGRSUGHW-UHFFFAOYSA-N
• SMILES: CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(C6=CC(=O)OC6)CCC5(O)C4CCC3(O)C2)C(O)C(O)C1O